Project Number 2P01AG000538-34A1 Agency/Funding Organization NIA Funding Year 2014 View Full Project Details for INTRACELLULAR AMYLOID ACCUMULATION, INNATE IMMUNITY AND PATHOGENESIS Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 7. Circuits and Synapses a. Synaptic Plasticity and Synaptic Dysfunction Researcher and Organization Principal Investigator GLABE, CHARLES G Principal Investigator First Name CHARLES Principal Investigator Last Name GLABE Awardee Organization UNIVERSITY OF CALIFORNIA IRVINE Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PAR-11-066: NIA PROGRAM PROJECT APPLICATIONS (P01) FY Overall Cost $284,076 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official WISE, BRADLEY C Related Resources Repository [AlzPED] HuCNS-SC Human NSCs Fail to Differentiate, Form Ectopic Clusters, and Provide No Cognitive Benefits in a Transgenic Model of Alzheimer's Disease. [AlzPED] Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization. [AlzPED] Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. [AlzPED] Low Concentrations of Anti-Abeta Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology [AlzPED] Reductions in Aβ-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation [AlzPED] Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.